Dr Agnieszka Michael
Senior Lecturer
Qualifications: MD PhD
Email: a.michael@surrey.ac.uk
Phone: Work: 01483 68 8546
Room no: 04 PGM 03
Office hours
9am-5pm Mon-Fri
Further information
Biography
Qualifications
PhD October 2006
MRCP UK July 1998 London
PLAB October 1995 London
MBBS June 1993 Medical School Wroclaw Poland
Previous Positions
05 SEPT’ 06- 09 DEC’07 Guy’s and St Thomas’ NHS FT, Specialist Registrar rotation
05 MAR’ 06- 04 SEPT’ 06 St George’s Hospital, Haemato-Oncology, Specialist Registrar
05 SEPT’ 05- 04 MARCH’ 06 Guy’s and St.Thomas’ NHS FT, Specialist Registrar
01 JUL’ 05 - 04 SEPT’ 05 St George’s Hospital London, Specialist Registrar
01 MAY’ 01 – 30 OCT’ 04 Clinical research fellow , PhD project,
01 JUNE’ 99-30 APRIL’ 01 St. George’s Hospital, Specialist Registrar rotation
01 APR’ 99-30 MAY’ 99 Royal Marsden Hospital, Breast Unit, Specialist Registrar
SHO posts:
AUG’ 98-FEB’ 99 Royal Marsden Hospital, Sutton,
FEB’ 96-AUG’ 98 Two-year medical rotation in Havering Hospitals in Essex.
Research Interests
Biomarkers for Cancer
Ovarian Cancer
Publications
Journal articles
- . (2012) 'Low grade serous ovarian carcinoma with metastases to the sternum and ribs.'. Pathology, England: 44 (5), pp. 481-482.
- . (2012) 'Advances in the treatment of ovarian cancer: a potential role of antiinflammatory phytochemicals.'. Discov Med, United States: 13 (68), pp. 7-17.
- . (2011) 'ENGRAILED-2 (EN2): A HIGHLY SPECIFIC URINARY BIOMARKER FOR THE EARLY DIAGNOSIS OF PROSTATE CANCER'. ELSEVIER SCIENCE BV EUR UROL SUPPL, 10 (2), pp. 64-64.
- .
(2011) 'Engrailed-2 (EN2): a tumor specific urinary biomarker for the early diagnosis of prostate cancer.'. Clin Cancer Res, United States: 17 (5), pp. 1090-1098.Full text is available at: http://epubs.surrey.ac.uk/2751/
Abstract
Prostate cancer (PC) is the second most common cause of cancer related death in men. A number of key limitations with prostate specific antigen (PSA), currently the standard detection test, has justified evaluation of new biomarkers. We have assessed the diagnostic potential of Engrailed-2 (EN2) protein, a homeodomain-containing transcription factor expressed in PC cell lines and secreted into the urine by PC in men.
- . (2011) 'HOX genes in pancreatic development and cancer.'. JOP, Italy: 12 (3), pp. 216-219.
- .
(2011) 'HOX genes in ovarian cancer'. Journal of Ovarian Research, 4 (1)Full text is available at: http://epubs.surrey.ac.uk/711372/
Abstract
The HOX genes are a family of homeodomain-containing transcription factors that determine cellular identity during development. Here we review a number of recent studies showing that HOX genes are strongly expressed in ovarian cancer, and that in some cases the expression of specific HOX genes is sufficient to confer a particular identity and phenotype upon cancer cells. We also review the recent advances in elucidating the different functions of HOX genes in ovarian cancer. A literature search was performed using the search terms HOX genes (including specific HOX genes), ovarian cancer and oncogenesis. Articles were accessed through searches performed in ISI Web of Knowledge, PubMed and ScienceDirect. Taken together, these studies have shown that HOX genes play a role in the oncogenesis of ovarian cancer and function in the inhibition of apoptosis, DNA repair and enhanced cell motility. The function of HOX genes in ovarian cancer oncogenesis supports their potential role as prognostic and diagnostic markers, and as therapeutic targets in this disease. © 2011 Kelly et al; licensee BioMed Central Ltd.
- . (2010) 'CYTOREDUCTIVE NEPHRECTOMY IN THE TYROKINASE INHIBITOR ERA'. MARY ANN LIEBERT INC J ENDOUROL, 24, pp. A303-A303.
- .
(2010) 'Emergence of potential biomarkers of response to anti-angiogenic anti-tumour agents.'. Wiley-Blackwell International Journal of Cancer, United States: 127 (6), pp. 1251-1258.doi: 10.1002/ijc.25389Full text is available at: http://epubs.surrey.ac.uk/209783/
Abstract
Anti-angiogenic agents targeting tumour vasculature have an established place in clinical practice, and new data are constantly emerging. However, despite rapid clinical uptake, a very large number of questions regarding these agents remain unanswered. One of the main hurdles in clinical practice is lack of accurate and feasible ways of assessing response to drug beyond tumour reduction on conventional imaging. This review summarises recent developments in the field of biomarkers of response to anti-VEGF drugs.
- .
(2010) 'Targeting HOX and PBX transcription factors in ovarian cancer'. BIOMED CENTRAL LTD BMC CANCER, 10 Article number ARTN 89 Full text is available at: http://epubs.surrey.ac.uk/227161/
- .
(2010) 'Activation and Genetic Modification of Human Monocyte-Derived Dendritic Cells using Attenuated Salmonella typhimurium'. THESCIENTIFICWORLD LTD THESCIENTIFICWORLDJOURNAL, 10, pp. 393-401.doi: 10.1100/tsw.2010.37Full text is available at: http://epubs.surrey.ac.uk/209786/
- .
(2009) 'Prostate cancer chemotherapy in the era of targeted therapy'. NATURE PUBLISHING GROUP PROSTATE CANCER AND PROSTATIC DISEASES, 12 (1), pp. 13-16.doi: 10.1038/pcan.2008.32Full text is available at: http://epubs.surrey.ac.uk/209787/
- . (2007) 'Prognostic significance of erythropoietin expression in human renal cell carcinoma.'. BJU Int, England: 100 (2), pp. 291-294.
- .
(2007) 'Disease regression in malignant melanoma: Spontaneous resolution or a result of treatment with antioxidants, green tea, and pineapple cores? A case report'. SAGE PUBLICATIONS INC INTEGR CANCER THER, 6 (1), pp. 77-79.Full text is available at: http://epubs.surrey.ac.uk/210398/
- .
(2007) '13-cis-Retinoic Acid in Combination with Gemcitabine in the Treatment of Locally Advanced and Metastatic Pancreatic Cancer - Report of a Pilot Phase II Study'. W B Saunders Clinical Oncology, 19 (2), pp. 150-153.doi: 10.1016/j.clon
- . (2006) 'A phase I study of OncoVEX(GM-CSF), a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor'. AMER ASSOC CANCER RESEARCH CLINICAL CANCER RESEARCH, 12 (22), pp. 6737-6747.
- . (2005) 'Delayed disease progression after allogeneic cell vaccination in hormone-resistant prostate cancer and correlation with immunologic variables'. Clin Cancer Res, 11 (12), pp. 4469-4478.
- . (2001) 'Preliminary results of phase I/II study to investigate the use of gemcitabine in combination with ralitrexed in locally advanced or metastatic adenocarcinoma of the pancreas'. CHURCHILL LIVINGSTONE BRITISH JOURNAL OF CANCER, 85, pp. 55-55.
Conference papers
- . (2011) 'The effect of age on first-line sunitinib treatment in patients with renal cell carcinoma (RCC).'. J Clin Oncol 29: 2011 (suppl; abstr e15096), Chicago USA: ASCO
- . (2011) 'Pharmacokinetic (PK)/pharmacodynamic (PD) analysis of escalating repeat doses of the AKT inhibitor GSK2141795 (GSK795) in patients (pts) with ovarian cancer.'. J Clin Oncol 29: 2011 (suppl; abstr 5064), Chicago USA: ASCO
- . (2011) 'EN2: A candidate antigen for the development of targeted therapies in ovarian cancer.'. JCO, Chicago: ASCO (J Clin Oncol 29: 2011 (suppl; abstr e15528))
- . (2011) 'The sun study-a biobank of sequential blood samples from patients with prostate cancer'. WILEY-BLACKWELL BRITISH JOURNAL OF SURGERY, Royal Coll Surgery, Dublin, IRELAND: Annual Meeting of the Society-of-Academic-and-Research-Surgery 98, pp. 50-50.
- . (2010) 'Evaluation of EN2 as a urine-based biomarker for prostate cancer.'. J Clin Oncol 28, 2010 (suppl; abstr e15129), Chicago USA: ASCO
- . (2010) 'The impact of age on first-line chemotherapy treatment of epithelial ovarian cancer and primary peritoneal carcinoma'. Chicago USA: ASCO (J Clin Oncol 28:15s, 2010 (suppl; abstr 5118))
